Silence Therapeutics Plc American Depository Share (SLN)

Nasdaq: SLN · Pharmaceutical Preparations · London · filing with the SEC since 2010

Full chart Alerts Compare

Grade3.4

◀ Past 5.0● Present 2.2▶ Future 3.4

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Silence Therapeutics Plc American Depository Share

Nine metrics read from its own filings, by tense

Headline grade

3.4/10

◀ Past5.025% of the headline

● Present2.235% of the headline

▶ Future3.440% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.0/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Silence Therapeutics Plc American Depository Share's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

2.8/10

What has it actually done, year after year?

-70.4% a year over 4 filed years; profitable in 0 of 4.

weight 45% of this tense · 28th percentile among 323 sector filers · read for its customers

From the record

Silence Therapeutics Plc American Depository Share's 4 filed years say what it did: revenue went from $22 million in fiscal 2022 to $559 thousand in fiscal 2025, down 70.4% a year; it rose in 2 of 3 years; the deepest fall was 99% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

revenue growth over the filed span-70.4%bottom 1% of its family
the share of years revenue rosetop 41% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak98.7%bottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.9/10

How has it treated the people who own it?

SI estimate 5.9/10, confidence 35 of 100 (one part).

weight 33% of this tense · 59th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 41% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Silence Therapeutics Plc American Depository Share's shareholder treatment is put at 5.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 41% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.2/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

3.5/10

Is it financially healthy right now?

ROE -142%: lost 142¢ per shareholder dollar. Leverage 53%: owes 53¢ per asset dollar.

weight 45% of this tense · 35th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Silence Therapeutics Plc American Depository Share lost about 142 cents for every dollar of shareholders' money, and gross profitability: its products earned about 0 cents per dollar of everything the company owns. Leverage: it owed about 53 cents per dollar of assets, and net share issuance: its share count grew 2.1% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 32% of its family
return on equitybottom 24% of its family
gross profit against assetsbottom 8% of its family
the share count against the year beforetop 22% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.0/10

How strong is its position in its industry?

bottom 10% of 315 in its family; net margin -15851.9%.

weight 22% of this tense · 10th percentile among 315 sector filers · read for its customers

From the record

Silence Therapeutics Plc American Depository Share's standing among 315 graded names in its industry family: revenue of $559 thousand in fiscal 2025 ranks in the bottom 17% by size; a net margin of -15851.9% ranks in the bottom 9%; revenue growth of -70.4% a year over the last 3 filed years ranks in the bottom 4% (its annual reports).

What it rests on

revenue against the family$559,000bottom 17% of its family
net margin-15851.9%bottom 9% of its family
three-year revenue growth-70.4%bottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

1.1/10

What are the people in charge doing?

SI estimate 1.1/10, confidence 35 of 100 (one part).

weight 33% of this tense · 11th percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 11% of 415 in its family; the record of its people begins on 2025-01-02 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 1.9 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read: The record of its people begins on 2025-01-02 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 1.9 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 415 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Silence Therapeutics Plc American Depository Share's leadership is put at 1.1 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 11% of 415 in its family; the record of its people begins on 2025-01-02 (a listing, a merger or a first filing under the rules) and most of the people in charge have filed since then, so the record shows a floor of 1.9 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.4/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.1/10

How much room does it have to grow?

bottom 41% of 273 in its family for room to expand.

weight 33% of this tense · 41st percentile among 273 sector filers · read for itself

From the record

Silence Therapeutics Plc American Depository Share's room to grow, from the newest filed statements (fiscal 2025): cash of $11 million against no long-term debt tagged leaves 8.6% of its assets as net cash, bottom 23% of its family; cash from operations less capital spending is -11149.6% of revenue (bottom 7%); a gross margin of 61.5% (bottom 39%); research spending of 12120.4% of revenue (top 5%) (its annual report).

What it rests on

cash less debt against assets8.6%bottom 23% of its family
cash from operations less capital spending against revenue-11149.6%bottom 7% of its family
gross margin61.5%bottom 39% of its family
research spending against revenue12120.4%top 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.2/10

What could actually drive growth from here?

bottom 42% of 306 in its family for growth drivers.

weight 45% of this tense · 42nd percentile among 306 sector filers · read for its customers

From the record

Silence Therapeutics Plc American Depository Share's growth drivers, from the filed years to fiscal 2025: revenue grew -70.4% a year over the last three filed years against -70.4% over all 4, speeding up (top 40% of its family); the newest year grew -98.7% (bottom 1%); research spending grew 15.9% a year (top 29%); capital spending grew -31.7% a year (bottom 36%) (its annual reports). Silence Therapeutics Plc American Depository Share tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 40% of its family
the newest year's revenue growth-98.7%bottom 1% of its family
three-year growth of research spending15.9%top 29% of its family
three-year growth of capital spending-31.7%bottom 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

0.8/10

Did its newest year beat what its own record pointed to?

bottom 8% of 233 in its family for expectations against reality.

weight 22% of this tense · 8th percentile among 233 sector filers · read for its shareholders

From the record

Silence Therapeutics Plc American Depository Share's newest year against its own record: revenue of $559 thousand in fiscal 2025 came in 99.1% below the $61 million its prior three years' pace pointed to (bottom 1% of its family); net income of $89 million against a prior three-year average of $50 million (bottom 20%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 5%) (its annual reports).

What it rests on

revenue against the prior three years' pace-99.1%bottom 1% of its family
net income against the prior three years' average-77%bottom 20% of its family
net margin against its prior averagedown more than 100 pointsbottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SLN · research, not advice